USA: A recent analysis from the ATLAS-OLE study has provided promising insights into the long-term safety and efficacy of fitusiran, an antithrombin-based dose regimen, in individuals with hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback